Clinical trial
Insulin Glulisine in Type 2 Diabetic Patients
NCT00360698 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00360698 |
|---|---|
| Title | Insulin Glulisine in Type 2 Diabetic Patients |
| Official title | Comparison of Two Therapeutic Strategies for Treating Type 2 Diabetic Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs : 6-month Proof of Concept Study. |
| Acronym | Basal Plus |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Insulin Glargine, Glimepiride, Insulin Glulisine, Metformin |
| Enrollment | 106 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Aug 7, 2006 |
| Last update posted | Aug 8, 2011 |
| Countries | Russia, United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: